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Abstract
Sporadic and familiar amyotrophic lateral sclerosis (ALS) cases presented lower
cholinergic activity than in healthy individuals in their still preserved spinal
motoneurons (MNs) suggesting that cholinergic reduction might occur before
MN death. To unravel how and when cholinergic function is compromised, we
have analyzed the spatiotemporal expression of choline acetyltransferase (ChAT)
from early presymptomatic stages of the SOD1G93A ALS mouse model by con-
focal immunohistochemistry. The analysis showed an early reduction in ChAT
content in soma and presynaptic boutons apposed onto MNs (to 76%) as well
as in cholinergic interneurons in the lumbar spinal cord of the 30-day-old
SOD1G93A mice. Cholinergic synaptic stripping occurred simultaneously to the
presence of abundant surrounding major histocompatibility complex II
(MHC-II)-positive microglia and the accumulation of nuclear Tdp-43 and the
appearance of mild oxidative stress within MNs. Besides, there was a loss of
neuronal MHC-I expression, which is necessary for balanced synaptic stripping
after axotomy. These events occurred before the selective raise of markers of
denervation such as ATF3. By the same time, alterations in postsynaptic cholin-
ergic-related structures were also revealed with a loss of the presence of sigma-1
receptor, a Ca2+ buffering chaperone in the postsynaptic cisternae. By
2 months of age, ChAT seemed to accumulate in the soma of MNs, and thus
efferences toward Renshaw interneurons were drastically diminished. In conclu-
sion, cholinergic dysfunction in the local circuitry of the spinal cord may be
one of the earliest events in ALS etiopathogenesis.
Introduction
Dysfunction of the cholinergic system is a common fea-
ture in Alzheimer’s disease, Huntington’s disease, and
amyotrophic lateral sclerosis (ALS). In the formers, little
is known surprisingly about the implication of cholinergic
dysfunction with disease etiopathogenesis. In ALS, cholin-
ergic diminution has been presumed to be associated in
late stages, with motoneuron (MN) loss. Choline
acetyltransferase (ChAT, acetyl CoA: choline O-acetyl-
transferase, EC 2.3.1.6), the enzyme responsible for the
biosynthesis of acetylcholine, is the most specific indicator
for monitoring the functional state of cholinergic neurons
in the central and peripheral nervous systems. ChAT
mediates the reaction involving the transfer of an acetyl
group from acetyl coenzyme A to choline to form
acetylcholine (ACh) at the synaptic endings of cholinergic
neurons. ChAT is synthesized in the perikaryon of cholin-
ergic neurons, and a minor proportion is transported by
fast axonal transport, mainly mediated by kinesins (Ray
et al. 1999). At the synaptic terminals, ACh is synthesized
in the cytoplasm and stored into synaptic vesicles by the
vesicular acetylcholine transporter (VAChT).
ALS selectively affects MNs in the brain and spinal cord,
resulting in progressive weakness and wasting of muscles.
Histopathologically, there is loss of upper MNs in the cere-
bral motor cortex, and prominent loss of lower cholinergic
MNs in the motor nuclei of the brainstem and the anterior
horn of the spinal cord (Cleveland and Rothstein 2001).
Both sporadic and familiar cases of ALS present a marked
reduction in ChAT activity in the anterior horn of the
spinal cord (Wang et al. 1997). Far from being only a
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reflection of neuronal loss, microassay analysis of ChAT
activity of single neurons has demonstrated that large, pre-
served neurons at an early stage of the disease show lower
ChAT activity than control neurons (Kato 1989; Oda et al.
1995). Morphologic studies have also demonstrated a
marked loss of ChAT mRNA in spinal cord of ALS patients
by in situ hybridization (Virgo et al. 1992). These findings
suggested that low expression of ChAT in the spinal cord
may represent an early abnormality in the pathogenesis of
ALS (Oda 1999), starting long before MN death. However,
the causes of sporadic ALS remain obscure. Since the dis-
covery of the genetic linkage of mutations in superoxide
dismutase 1 (SOD1) gene with familial ALS patients, one
of the highlighted putative mechanisms is that degenera-
tion of MNs is closely linked to involvement of SOD1 in
both sporadic and familial cases (Bosco et al. 2010). It is
proposed that the occurrence of misfolded SOD1 triggers a
cascade of neurodegeneration by “gains-of-function”
through activation of glutamate-mediated excitotoxicity,
which induces an uncontrolled increase of intracellular cal-
cium concentration (de Carvalho and Swash 2011). Data
regarding cholinergic activity in animal models carrying
SOD1 mutations are mainly reported linked to MN loss in
the symptomatic phase (Crochemore et al. 2005; Alves
et al. 2011).
Nevertheless, a question that remains to be solved is
how and when cholinergic function is compromised along
the neurodegenerative process. In order to answer these
questions, we have analyzed the spatiotemporal expression
of ChAT, considering local cholinergic circuitry, efferenc-
es, and afferences, within the spinal cord from early pre-
symptomatic until symptomatic stages of an ALS mouse
model. The results obtained highly the importance of the




Experiments were performed in transgenic mice carrying
the mutation G93A in SOD1 gene and in nontransgenic
wild-type (WT) littermates considered controls. SOD1G93A
high copy mice (Tg[SOD1-G93A]1Gur) were obtained
from the Jackson Laboratory (Bar Harbor, ME), with
B16xSJL background. These mice were bred and main-
tained as hemizygotes by mating transgenic males with F1
hybrid (B6SJLF1/J) females obtained from Charles River
Laboratories (Belgium). Animals were bread at the Animal
Supply Services, Unidad Mixta de Investigacio´n, University
of Zaragoza, and were cared for and handled in accordance
with the guidelines of the European Union Council
(86/609/UE) and Spanish regulations (BOE 67/8509-12;
BOE 1201/2005) on the use of laboratory animals.
Experimental procedures were approved by the local Ethics
Committee of the Universitat Auto`noma de Barcelona.
Transgenic mice were identified by polymerase chain
reaction amplification of DNA extracted from the tail.
Studies were performed in groups of 1-, 2-, and 3-month-
old female mice (n = 8 each). One- and 2-month-old
SOD1G93A mice are considered to be in early and adult
presymptomatic stages of disease, respectively, whereas
3-month-old mice had an early symptomatic phenotype by
behavioral (Chiu et al. 1995) and electrophysiological
testing (Mancuso et al. 2011).
Immunohistochemistry
Animals were anesthetized with sodium pentobarbital
(50 mg/kg i.p.), and perfused transcardially with phosphate
buffered saline (PBS), followed by 4% paraformaldehyde in
0.1 mol/L PB, pH 7.4 at 4°C. The spinal cord was removed,
divided into lumbar, thoracic and cervical segments, post-
fixed for 24 h and cryopreserved in 30% sucrose in PBS at
4°C. Transverse sections (40 lm thick) were obtained with
a cryostat (Leica, Heidelberg, Germany) individually placed
on 96-well plates in Olmos solution and stored at 20°C.
The sections were distributed in 50 series of five sections
each, and each series was prepared for immunohistochemi-
cal analysis by blocking with 10% bovine serum, 0.3% Tri-
ton X-100 in tris-buffered saline for 1 h at room
temperature, followed by incubation with different combi-
nations of up to three primary antibodies against synapto-
tagmin (clone Mab48, Developmental Studies Hybridoma
Bank, IA), nitrotyrosine (Millipore, Bedford, MA), human
HCA-ABC antigen (MHC-I, DAKO, Glostrup, Denmark),
MHC-II-APC (eBiosciences, SanDiego, CA), Iba1 (Wako,
Tokyo, Osaka, Japan), sigma 1 Receptor (Sig1-R, Santa
Cruz Biotechnologies, Santa Cruz, CA) and ChAT (Milli-
pore) overnight at 4°C. After washes, sections were incu-
bated for 1 day at 4°C with biotinylated secondary
antibodies (Vector, Burlingame, CA, 1: 200) with Cy-2,
Cy-3, or Cy-5 conjugated donkey anti-rabbit, anti-mouse,
or anti-goat IgGs antibodies (Jackson Immunoresearch,
West Grove, PA, 1:200). Slides were counterstained with
DAPI (4´,6-diamidino-2-phenylindole) (Sigma, St Louis,
MO, 1: 1000) and mounted with Fluoromount (Southern-
Biotech, Birmingham, AL). Omission of the primary anti-
bodies resulted in no detectable staining. At lumbar levels,
the analysis was focused in MNs from L4–L5 segments that
provide innervation to hindlimb muscles. Sections from
different time points of transgenic and control animals
were processed in parallel for immunohistochemistry
and data represent an accumulation of different day
performances. Confocal microscope examinations were
performed with a Leica TCS SP2 AOBS laser scanning con-
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focal system (Leica). All MNs were analyzed in a z-plane
containing the nucleus and captured using the FV10-ASW
1.7 Viewer software. Confocal images were obtained using
two separate photomultiplier channels, either concurrently
or in separate runs, and were separately projected and
merged using a pseudocolor display showing green for Cy2,
red for Cy3, magenta for Cy5, and blue for DAPI. When
densitometric analysis was performed, images of the ventral
area of the spinal cord were taken under the same exposure
time, sensibility, and resolution for each marker analyzed,
with the aid of a digital camera (Olympus DP50) attached
to the microscope (Olympus BX51). The microphoto-
graphs were transformed to a gray scale and analyzed using
ImageJ software. Immunoreactivity was assessed by calcu-
lating the integrated density, after defining a threshold for
background correction. The integrated density of a region
of interest (ROI), defined as the area above the threshold
for the mean density minus the background, was measured.
The ROIs were selected on the gray matter of the ventral
horn and had an area of 4900 lm2 for ChAT-stained ven-
tral horn MNs and 1300 lm2 for cholinergic ChAT-stained
interneurons. The average cell size was similar between the
genotypes and stable over the observation period.
Quantification of ChAT-positive synaptic
boutons
The quantitative evaluation of synaptic boutons was car-
ried out by confocal analysis. Projection of section images
(0.68 lm) obtained from a Z-plane screening of each
sample was maximized to obtain single image of uniform
thickness (10 lm) that contained the whole motoneuro-
nal soma. We counted both the number of large ChAT-
positive varicosities and the synaptotagmin-positive large
terminals apposing the soma of the MNs per perimeter
using the Metamorph 2.0 software. The evaluation
included 24–36 MNs per spinal cord at L4 level (in 3–4
animals per phenotype).
Molecular analysis
Half lumbar spinal cord from WT and transgenic animals
at different ages were obtained and processed for either
RNA or protein analysis. Protein was obtained by collecting
the tissue in lysis buffer (20 mmol/L HEPES [4-(2-hydro-
xyethyl)-1-piperazineethanesulfonic acid buffer], 250 mmol/L
sucrose, 1 mmol/L EGTA [ethylene glycol tetraacetic
acid], 1 mmol/L EDTA [ethylenediaminetetraacetic acid],
pH 7.4). Lysates were homogenated with Pellet pestle
(Sigma, St Louis, MO) and spin at 800g. An equal
amount of protein (20 lg/lane) was resolved in 10%
SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel)
and electrotransferred to PVDF (polyvinylidene difluoride)
membranes (Millipore). Membranes were blocked with
6% nonfat dry milk in PBS (140 mmol/L NaCl,
2.7 mmol/L KCl, 4.3 mmol/L Na2HPO4H2O, and
1.5 mmol/L KH2PO4) for 1 h at room temperature and
incubated overnight with the corresponding primary
antibody, ChAT (1:1000, Chemicon), or actin (1:10,000,
Sigma). After several washing, membranes were incubated
for 1 h with an appropriate secondary antibody conju-
gated with horseradish peroxidase (1:3000, anti-mouse-
HRP; Dako, Denmark) and anti-rabbit-HRP (Invitrogen,
Carlsbad, CA). Blots were developed using a chemilumi-
niscent mix 1:1 (0.5 mol/L luminol, 79.2 mmol/L p-coum-
aric acid, 1 mol/L Tris-HCl pH 8.5 and 8.8 mol/L
hydrogen peroxide, 1 mol/L Tris-HCl pH 8.5) and
exposed to enzymatic chemiluminiscence (ECL) films
(Amersham Pharmacia Biotech, Buckinghamshire, UK).
The apparent molecular weight of proteins was deter-
mined by calibrating the blots with prestained molecular
weight marker (All Blue, Pierce). Densitometry was carried
out using ImageJ program.
The other half of the tissue was obtained in RNAlater
(Qiagen, Valencia, CA) and processed with Quiagen easy
kit following manufacturer instructions. One microgram
of RNA was reverse transcribed using 10 mmol/L DTT,
200 U Superscript II RNase H reverse transcriptase (Invi-
trogen, Foster City, CA), 10 U RNase Out Ribonuclease
Inhibitor (Invitrogen) and 1 mol/L oligo(dT), 1 mol/L of
random hexamers (BioLabs, Beverly, MA). The reverse
transcription cycle conditions were 25°C for 10 min, 42°C
for 1 h, and 72°C for 10 min. The primers used for
RT- and real-time polymerase chain reaction (PCR) were
ChAT (F, 5′-TGGATGGTCCAGGCACTGGAGACC-3′; R,
5′-GTCA TACCAACGATTCGCTCCATTCA-3′) and glyc-
eraldehyde-3-phosphate dehydrogenase (Gapdh) (F, 5′-AC
CACCATGGAGAAGGCCGG-3′; R, 5′-CTCAGTGTAGCC
CAAGATGC-3′). PCR products yielded fragments smaller
than 150-bp length. Real-time PCR (ABI prism 7700 detec-
tion system, PE Applied Biosystems, Foster City, CA) was
performed using Brilliant III Ultra-Fast SYBR® Green
qPCR master mix (Agilent Technologies, Santa Clara, CA,
USA). We previously fixed the optimal concentration of
the cDNA to be used as template for each gene analysis to
obtain reliable CT (threshold cycle) values for quantifica-
tion. Four samples were used per condition and each sam-
ple was run in triplicate. The thermal cycling conditions
were 50°C for 2 min, 95°C for 10 min, and 40 cycles of
95°C for 15 sec, 60°C for 1 min. CT values were obtained
and analyzed with the ABI prism 7700 SDS Software. Fold
change in gene expression was estimated using the CT
comparative method (2ΔΔCT) normalizing to Gapdh CT
values and relative to the average of control samples. Melt-
ing curves confirmed amplification of solely one PCR
product for all qPCRs.
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Statistical analysis
Data are expressed as the mean ± SEM. Comparisons
between groups of mice of different ages were made by
one-way analysis of variance (ANOVA) with post hoc
Dunnett’s multiple comparison test for IHC analysis
using GraphPad Prism 5.01 software. For qPCR analysis,
it was used a nonparametric Mann–Whitney test. Statisti-
cal significance was set at P < 0.05. The number of ana-
lyzed MNs and number of animals are indicated in the
results section, as well in the figure legends.
Results
ChAT immunoreactivity
In the WT mice at all ages analyzed, normal ChAT
expression was located in the perikaryon, nucleus and
processes as well as in presynaptic terminals apposed onto
MNs at the ventral horn of the spinal cord. We also
observed ChAT within cholinergic interneurons placed
around the central canal (lamina X) and extended to the
lateral edge in the gray matter.
When analyzing its temporal expression, we observed
a transient reduction in CHAT immunoreactivity within
the soma of MNs in transgenic mice carrying the muta-
tion G93A in SOD1 gene (SOD1G93A) compared with
the WT littermates (Fig. 1). We analyzed separately lum-
bar and thoracic segments as this mouse model is
known to present a progressive caudal to rostral degen-
eration of the MNs (Gurney et al. 1994). We found that
ChAT immunoreactivity was significantly decreased in
ventral MNs at 1 month of age but close to normal at 2
and 3 months (Fig. 1A–C). This reduction was observed
in practically all MNs located either lateral or medially
in the ventral horn at different thoracic (decrease of
80 ± 2% at 1 month, n = 13–31) and lumbar (69 ± 3%,
n = 13–64) levels. We also observed that the ChAT con-
tent was normally localized within the whole MN soma,
including the nucleus, in the 1-month-age SOD1G93A
mice, but it seemed to be mainly located in the cyto-
plasm in the 3-month-age mice observed by confocal
analyses. Besides, CHAT-labeled processes were sharper
and shorter from 2 months of age (data not shown).
We performed Western blot analysis and quantitative
PCR to analyze the expression level of ChAT protein
and transcript, respectively, in lumbar sections from 1
and 3 month of age animals. We observed no significant
differences at protein level at any time point between
transgenic and control littermate animals; however, it
was a marked reduction in the transcript of ChAT in






Figure 1. Early transient ChAT reduction in spinal MNs of transgenic
SOD1 mice. (A) Immunofluorescent microphotographs showing ChAT
content in MNs at the L4–L5 spinal cord ventral horn of
nontransgenic wild-type (WT) littermates or transgenic SOD1 mice
(Tg) at 1, 2, and 3 months of age. Scale bar, 50 lm. (B, C) Bar
graphs representing average ± SEM of the integrated density of ChAT
content within a ROI of 4900 lm2 in single MNs at lumbar (B) and
thoracic levels (C) of the spinal cord of WT and Tg SOD1 mice at
different ages (n = 4 animals/group, n = 13–65 MNs per animal). A
transient reduction was observed in Tg mice by 1 month of age.
***P < 0.0001. (D) ChAT mRNA transcript analysis by quantitative
PCR of lumbar spinal cord at 1 and 3 months of age. Bars represent
the average fold change respect to their controls and gapdh mRNA
expression, n = 4, *P < 0.05. (E) Western blot results of murine ChAT
protein content in the same samples and bar graph representing the
content average respect to the b-actin.
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In order to investigate whether it was a general effect
affecting the production of ChAT independently of the
type of neuron or it was specific for MNs, we analyzed
also the cholinergic interneurons present in lamina X that
innervate MNs at the lumbar level. We observed that cho-
linergic interneurons presented also a reduction in ChAT
content within their soma (61 ± 8%, n = 13) at 1 month
of age, which increased at 2 months but it was still signif-
icantly lower than in WT mice (Fig. 2).
These results indicated that there is a generalized, early,
and transient reduction in ChAT content in the soma and
processes of cholinergic neurons, both MNs and interneu-
rons of the spinal cord, in SOD1G93A mice at 30 days of
age. This decline persists in the processes but not in the
soma of MNs in older transgenic mice.
Quantitation of ChAT-positive boutons
As mentioned, ChAT was also observed in cholinergic ter-
minals that contact onto spinal MNs, which belong to
either recurrent axonal collaterals of interconnections
between MNs (Cullheim et al. 1977) (Lagerback et al.
1981) or innervation by cholinergic interneurons. These
inputs influence the MN excitatory and inhibitory balance,
which is altered in ALS. Those terminals apposing MN
somata are named C-boutons and represent one of the
largest terminals around their perimeter (3–7 lm in cat)
(Arvidsson et al. 1997). In order to analyze the ChAT con-
tent in these terminals, we counted ChAT-labeled boutons
apposed to MNs at L4–L5 in WT and SOD1G93A mice at 1
and 2 months of age. We found a marked decrease (76%)
in SOD1G93A mice already from 1 month of age (Fig. 3).
No statistical differences were found between nontransgen-
ic animals of 1 or 2 months of age. In order to correlate
the presence of ChAT content with the structural existence
of the synaptic terminal, we counted also the large synapt-
otagmin-positive boutons apposed to MNs somata (puta-
tively C-boutons). We found that their density was normal
at 1 month of age (10.2 ± 2 boutons/100 lm) although
only 39% of these boutons were ChAT positive (Fig. 3). In
contrast, the number of large synaptotagmin-positive bou-
tons decreased (5 ± 0.6 boutons/100 lm) by 2 months of
age and most of them were ChAT-positive boutons (82%).
These results indicated that the content of ChAT within
large boutons progressively diminished from 1 month of
age and the frequency of these cholinergic terminals tended
to be reduced in the 2-month SOD1G93A mice.
In the postsynaptic membrane of the MN, beneath
some cholinergic presynaptic boutons, there is a subsy-
naptic cistern. The cistern is thought to be continuous
with the rough endoplasmic reticulum (ER) and directly
associated with the function of the synapse (Nagy et al.
1993). In these cisterns, the sigma 1 receptor (Sig1-R) is
present to buffer Ca2+ entry overload (Mavlyutov et al.
2010). We found Sig-1R immunoreactivity at close prox-
imity of the synaptic clefts in a spotty appearance in
MNS of WT mice, but it was absent in lumbar MNs from
SOD1G93A mice of 1 month of age (Fig. 4). Curiously, it
was still present in thoracic MNs of the same animals
although in smaller spots than in the WT (Fig. 4).
Further evidences of cholinergic alterations were
observed in the local circuitry established between MNs
and Renshaw interneurons in the ventral horn. We labeled
Renshaw cells with anticalbindin and observed the cholin-
ergic boutons onto their surface. The presence of choliner-
gic terminals along their processes was diminished form
the 1-month-old SOD1G93A mice (Fig. 5). Also note the
lack of ChAT staining in the processes efferent from MNs.
In conclusion, these data indicate that ChAT activity
may be reduced in the synaptic terminals from very early
in the presymptomatic stage of the SOD1G93A mice. This
abnormality affects both afferences and efferences onto




Figure 2. Cholinergic interneurons have early decrease of ChAT in
the ALS mouse model. (A) Representative immunofluorescent
microphotographs showing ChAT labeling in cholinergic interneurons
(green) contrasted with cellular nuclear staining with DAPI (blue), near
the central canal at the lumbar spinal cord of wild-type (WT) and Tg
SOD1 mice. Arrows point some cholinergic interneurons. Scale bar,
50 lm. (B) Quantification of ChAT integrated density of staining (ROI
of 1300 lm2, around interneuronal soma) in these interneurons are
represented by mean ± SEM in a bar graph showing reduction most
marked in Tg animals of 1 month of age (n = 4 animals/genotype,
n = 13 neurons per animal). *P < 0.05.
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Figure 3. Early reduction of ChAT content
precedes loss of large synaptic boutons.
(A–C) Representative imunofluorescent
microphotographs showing ChAT (green),
synaptotagmin (Syn, red), and merged
images (yellow–orange staining in
colocalization) around MNs at the L4–L5
ventral horn of WT and transgenic mice of
1 and 2 months of age. Note an overall
reduction in ChAT-positive dots around
MNs in (B), and a change in the quality of
Syn dots with decreased density of large
ones apposing MNs in (C). (D–F) High
magnification microphotographs of MNs
from WT and transgenic mice of different
ages showing synaptic boutons apposing
to MNs. Note in (D), that all ChAT-positive
synaptic boutons matched with
synaptotagmin labeling while in (E), large
Syn-positive synaptic boutons have absent
or reduced ChAT content (arrows pointing
some of them). Note that some ChAT-
positive terminals seem to be larger than in
the WT mice. In (F), Syn-positive dots were
reduced in density and most of the largest
ones were ChAT positive. Scale bar, A–C,
50 lm; D–F, 10 lm. (G) Quantification of
the number of ChAT-positive boutons
apposing MN somata per 100 lm of
membrane perimeter (mean ± SEM).
(H) Percentage of large Syn-boutons that
are also ChAT positive (mean ± SEM).
***P < 0.0001 two-way analysis of
variance, post hoc Dunnet’s test.
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Synaptic stripping
To shed light about the reduction of large synaptotagmin-
positive boutons apposed to the MN soma, we examined
the presence of perineuronal microglia. It is known that
microglia is actively involved in the processes of synaptic
stripping that normally occur in response to peripheral
axotomy (Blinzinger and Kreutzberg 1968). We used Iba1
as a marker for microglia and observed the expression of a
major histocompatibility complex II (MHC-II) protein
that is overexpressed in phagocytic microglia (Bo et al.
1994). In the WT mice, independently of the age, MHC-II
was observed in both sparse microglia and within the MN
soma (Fig. 6A and B). In the SOD1G93A mice, already from
1 month of age, there was a loss of MHC-II neuronal
expression concurrent with abundant MHC-II-positive
microglia surrounding MNs (Fig. 6C and D).
Another member of the major histocompatibility
complex, MHC-I, is implicated in the cross-talk between
microglia and MNs for selective synaptic stripping during
development, plasticity, and regeneration (Huh et al.
2000). We observed that MHC-I was expressed within
MN soma and processes with a dotted pattern in WT
mice. In the SOD1G93A mice, MHC-I expression seemed
to be weaker than in WT, and it was practically absent at
2 months of age (Fig. 6E–G).
The presence of aggregated MHC-II-positive phagocytic
microglia surrounding MNs that present themselves a
downregulation of both MHC-I and MHC-II suggested
that altered synaptic stripping may be an early event in
the pathogenesis of MN degeneration.
Relation with oxidative and ER stress
In order to link the presence of two of the main processes
involved in ALS-associated neurodegeneration, oxidative,
and ER stress, with our observations regarding ChAT
altered expression, we analyzed the concurrence of these
events.
It has been observed that SOD1G93A mice start to show
detachment of neuromuscular junctions as early as 47 days
of age (Pun et al. 2006). Besides, this denervation triggers
the overexpression of ER stress markers in the MNs
(Saxena et al. 2009), being ATF3 the one appearing first in
the SOD1G93A mice. ATF3 is downstream ATF4 that forms
part of one the main branches of the response triggered by
ER stress. On the other hand, denervation and axotomy
often shut ChAT expression off in the MNs (Penas et al.
2009). Thus, we were interested in linking these early events
to sequence its order of appearance and establish a putative
causal link. When analyzing ATF3 expression by immuno-
histochemistry, we observed that it was notably increased
within the nucleus of only selective spinal MNs from 2-
month-old SOD1G93A mice, but it was completely absent in
animals at 1 month of age (Fig. 7). Therefore, cholinergic
dysfunction appears to precede ER stress in the MNs.
Considering that SOD1 manages the accumulation of
reactive species, and oxidative stress has been related to
the neurodegenerative process in ALS (Basso et al. 2009),
we analyzed the time course of accumulation of nitrosa-
tive reactive species. We analyzed nitrotyrosine levels in
gray and white matter of the spinal cord, as nitrosative
reactive species have been early detected in the SOD1G93A
mice. Besides, high levels of nitrotyrosine activate micro-
glia to initiate synaptic stripping (Moreno-Lopez et al.





Figure 4. Early loss of Sigma 1 receptor expression in lumbar MNs
from transgenic SOD1G93A mice at 1 month of age. Representative
confocal overlayed microphotographs showing Sig1-R (green)
localized in the postsynaptic sites within the MNs, and synaptotagmin
staining of presynaptic terminals (red) (left panels). The inset of top-
left panel shows a detail of close localization of both markers at
higher magnification. In the right panels, microphotographs show
DAPI staining to reveal the presence of the MN nucleus. WT panel
show a representative MN image from lumbar site although thoracic
site presented the same pattern (not shown). Note the absence of
Sig1-R immunoreactivity in lumbar MNs but still presence in thoracic
MNs (arrows) of the spinal cord from mutant transgenic mice of
1 month of age. Scale bar, 50 lm.
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absent in WT spinal cord; however, we observed that ni-
trotyrosine levels progressively increase in the gray matter
and within the MN soma in SOD1G93A mice, reaching
significantly higher values at 2 months of age (Fig. 7).
These data suggested that cholinergic alterations may
occur earlier than peripheral neuromuscular detachment
and consequently induced ER stress, but in parallel to the
initial accumulation of oxidative reactive species.
Tdp-43
Finally, considering that Tdp-43, also linked to ALS etio-
pathogenesis, is involved in multiple steps of RNA metab-
olism, including transcription, splicing, or transport of
mRNA (Lagier-Tourenne and Cleveland 2010), as well as
microRNA metabolism, and it has been recently shown to
target ChAT mRNA as well, (Buratti et al. 2010) we
wanted to analyze its expression at early presymptomatic
stages in this mouse model.
Tdp-43 was found normally present in both nucleus
and cytoplasm of the MNs in WT mice. In contrast, Tdp-
43 was markedly overexpressed and accumulated in the
nucleus but barely detected in the cytoplasm of spinal
MNs in the SOD1G93A mice already at 1 month of age
(Fig. 8). The same pattern was observed at 2 months. In
contrast, from the symptomatic stage, by 3 months of
age, Tdp-43 levels increased also in the cytoplasm of MNs
and in the nucleus of surrounding glial cells within the
spinal cord parenchyma.
In conclusion, both the levels and localization of Tdp-
43 in all the spinal MNs are severely affected early in the
presymptomatic stage in SOD1G93A mice, and parallels
the development of cholinergic dysfunctions.
Discussion
Synaptic cholinergic dysfunction is a common feature of
different neurodegenerative diseases, including ALS, but
Figure 5. Cholinergic inputs on Renshaw neurons are reduced in transgenic SOD1G93A mice. Representative confocal overlayed
microphotographs showing ChAT immunolabeling (green, left panels), calbindin labeling (red, middle panels) to reveal Renshaw interneurons and
merged images (left panels) from the ventral horn of lumbar spinal cord from wild-type and transgenic SOD1 mice. Arrows point some
cholinergic terminals on dendrites of Renshaw neurons that are hardly detected in transgenic mice. Scale bar, 50 lm.
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little is known regarding the possible relationship between
ChAT abnormalities and the pathogenesis of MN degen-
eration. A detailed longitudinal study performed in the
present work shows that there is a marked reduction of
neuronal ChAT content affecting synaptic function in the
local spinal cord circuitry of the transgenic SOD1G93A
mouse model of ALS as early as 30 days of age, an early
presymptomatic stage. Timely highlighted concurrent
events are Tdp-43 overexpression in the nucleus of MNs
and the presence of mild oxidative stress.
Loss of cholinergic synapses was reported in ALS
patients (Nagao et al. 1998) and subsequent studies of
central synaptic connections of lumbar spinal MNs sug-
gested that synaptic dysfunction precedes synaptic loss
(Matsumoto et al. 1994; Sasaki and Maruyama 1994;
Ikemoto et al. 2002). However, limited investigation tar-
geting ChAT directly has been carried out on ALS animal
models. In the SOD1G93A model, the most studied one,
ChAT activity has been analyzed either by enzyme activity
determination (Crochemore et al. 2005) or by Western
blot of whole spinal cord extracts (Alves et al. 2011).
These studies did not reveal any abnormalities before the
symptomatic phase and thus later cholinergic dysfunction
was attributed to MN loss. We confirm these observations
when analyzed the protein levels by Western blot of the
whole lumbar spinal extract. However, by using immuno-
histochemical analysis of ChAT expression, which is more
sensitive to demonstrate specific changes in levels and in
particular cells, we show for the first time that ChAT con-
tent is clearly reduced in soma of MNs and cholinergic
synaptic terminals very early, by 1 month of age, before
any loss of MNs occurs. We also observed this reduction
in cholinergic interneurons. These interneurons normally
make synapses onto MNs (putatively cholinergic C-bou-
tons) (Barber et al. 1984) to ensure that sufficient output
is generated by MNs to drive motor behavior (Miles et al.
2007; Zagoraiou et al. 2009). Thus, reduction of ChAT
levels in cholinergic interneurons and MN somata them-
selves contributes to the observed reduction in ChAT
content in the synaptic boutons apposed to spinal MNs.
Consistently, an early reduction in ChAT transcript con-
tent was also observed by that time suggesting that signal-
ing changes in neuronal metabolism are implicated.
Considering several early pathological events described in
SOD1G93A mice, we were trying to figure out the possible
cause linked to this early ChAT reduction. On one hand,
ALS has been proposed to be a distal axotomy type of
neurodegenerative disease (Dadon-Nachum et al. 2011).
In agreement with that, SOD1G93A mice show detachment
of neuromuscular junctions as early as 47 days of age, fol-
lowed by a severe loss of motor axons in the ventral root
between days 47 and 80, and electrophysiological studies







Figure 6. Early reduction of MHC-II and MHC-I expression within
MNs versus increment of MHC-II-positive surrounding microglia in
lumbar ventral horns of transgenic SOD1G93A mice from 1 month of
age. (A, B) Representative confocal projection of microphotographs
showing MHC-II expression (magenta, A) in both MNs and microglial
cells. MNs are recognized by its form and size (arrows) and microglia
is recognize by colabeling with IbaI showed in the adjacent panel
(green, B) at the lumbar ventral horn of WT mice of 1 month of age.
(C, D) In the transgenic SOD1G93A mice of the same age (tg1M),
abundant microglia expressing MHC-II is seen around MNs (arrows) in
(C). In (D), a merged image from (C) is shown to reveal the presence
of MNs by its expression of a constitutive and ubiquitous chaperone
(BiP, green in D). (E, F) Representative confocal overlayed
microphotographs showing ChAT immunolabeling (green, left panels)
and the progression of MHC-I labeling (red, right panels) in MNs from
wild-type and transgenic SOD1G93A mice of 1 and 2 months. WT
animals from 1 and 2 months of age present the same pattern as in
(E). Note progressive reduction of MHC-I within the MNs of
transgenic mice. Scale bar, A–D, 200 lm; E–G, 50 lm.
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of age (Mancuso et al. 2011), well before a-MN cell
bodies die around day 110 (Fischer et al. 2004; Dadon-
Nachum et al. 2011). Furthermore, disconnected vulnera-
ble MNs selectively overexpress markers of ER stress like
ATF3 by the same time (Saxena et al. 2009). As early
reduction of ChAT is a common event in damaged MNs
after peripheral disconnection (Wang et al. 1997; Kitzman
2006; Penas et al. 2009), a possibility was that the reduc-
tion observed in the SOD1G93A mouse model was merely
due to the initial distal detachment. However, we
observed that ChAT reduction occurred earlier, by
30 days of age, and before ATF3 overexpression. Besides,
ChAT reduction was observed in all the MNs, and not
only in the most vulnerable ones that selectively presented
ATF3 hallmark. Thus, the cause for this ChAT reduction
is not due to distal detachment, on the contrary it might
contribute to it.
On the other hand, we explore the existence of other
metabolic ALS-related changes coexisting by 1 month of
age. We observed the presence of mild oxidative stress
and a marked early nuclear Tdp-43 accumulation in the
MNs as concurrent early events to cholinergic reduction.
Tdp-43 is involved in multiple steps of RNA metabolism,
including transcription, splicing, or transport of several
mRNAs. Interestingly, ChAT is one of the target genes of
Tdp-43 (Buratti et al. 2010); thus, it might be directly
involved in ChAT downregulation although extensive
analyses should be performed to unravel this possibility.
It is also interesting to highlight that Tdp-43 has normally
















Figure 7. Nitro-oxidation and endoplasmic reticulum stress appear later than cholinergic alterations. (A, B) Representative confocal
microphotographs showing ChAT labeling (green) contrasted with nuclear staining with DAPI (blue) in left panels and ATF3 labeling (red) of the
same cells in right panels. Note that there is no immunoreactivity for ATF3 in WT mice but strong nuclear presence in some MNs of the ventral
horn of transgenic mice by 2 months of age. (C–E) Nitrotyrosine labeling (red) of the ventral horn spinal cord from WT and transgenic mice of 1
and 2 months of age (right panels). Note the progressive accumulation of nitrotyrosine in the parenchyma and within the MNs. Scale bar, A–B,
100 lm; C–E, 50 lm. (F) Bar graph representing mean ± SEM of integrated density of nitrotyrosine labeling in the ventral horn of the spinal cord
from WT and transgenic SOD1G93A mice.**P < 0.01 two-way analysis of variance, post hoc Dunnet’s test.
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ALS samples from patients and in samples from late
symptomatic SOD1G93A mouse model, by 4 months of
age (Cleveland and Rothstein 2001). We observed the
starting delocalization to the cytoplasm by 3 months of
age. Thus, Tdp-43 cellular localization changes might
occur in parallel to dynamic metabolic changes that
sequenced from early presymptomatic to late symptom-
atic stages. Therefore, detailed longitudinal studies should
be considered to give further clues onto the etiopathogen-
esis of the diseases and to look for early biomarkers. In
this regard, the concurrent mild oxidative stress early
observed might be determinant to cause different
molecular picture to that promoted by chronic or exten-
sive oxidative stress which is presented later on. From our
observations, we consider that the consequences of mild
oxidative stress on Tdp-43 expression profile deserve fur-
ther exploration considering its important impact on
RNA metabolism of MNs and particularly to ChAT
expression.
The early ChAT content reduction seems to have
relevant consequences as we observed synaptic stripping-
related events with loss of cholinergic innervations
affecting the local circuitry at the spinal cord. Interest-
ingly, we detected that ChAT content seems to accumu-
late abnormally in the perikaryon of MNs but diminished
in processes and terminals from 2 months of age in the
SOD1G93A mice. These terminals were both afferent cho-
linergic boutons apposed to MNs and efferences from
Figure 8. Tdp-43 is markedly accumulated in the MN nucleus of the transgenic SOD1G93A mice. Representative confocal microphotographs of
single sections where a MN nucleus is present (DAPI staining in blue) showing ChAT (green) and Tdp-43 (red) immunolabeling, and merged
images of MNs at the ventral horn of the lumbar spinal cord from wild-type and transgenic SOD1G93A mice of 1, 2, and 3 months. Note that all
pictures were performed at the same conditions of exposition. Scale bar, 50 lm.
ª 2013 The Authors. Published by Wiley Periodicals, Inc. 155
C. Casas et al. Presymptomatic Cholinergic Dysfunction in ALS
MNs to Renshaw cells. These observations are consistent
with recent results reporting that ChAT can be seques-
tered in the soma because misfolded SOD1, present in
the SOD1G93A mice, impede particularly its axonal trans-
port (Tateno et al. 2009). Therefore, first due to a down-
regulation and later on due to transport problems, ChAT
is persistently reduced at the terminals and consequently
lead to synaptic dysfunction that finally may end up with
the cholinergic synaptic reduction. These events would
affect the functionality of the local spinal cord circuitry.
A reduced cholinergic input onto Renshaw interneurons
may lead to less inhibition of synergic MNs to counteract
the powerful effect of excitatory volleys brought about by
glutamatergic stimulation. In consequence, MNs rest
more vulnerable to excitotoxicity as it is characteristic in
ALS (Pieri et al. 2003; Kuo et al. 2004). Moreover, dys-
function of Renshaw cells may precede the loss of glycin-
ergic synapses onto MNs that was described for this
mouse model to occur at symptomatic stage (Chang and
Martin 2009). In agreement, alteration of this local cir-
cuitry has been also observed in ALS patients that present
a decrease in recurrent inhibition (Raynor and Shefner
1994).
Our observations support the hypothesis that stripping
of synaptic, in particular cholinergic, contacts with MNs
might be one of the earliest events in ALS (Murray et al.
2010). Microglia has been reported to initiate stripping
events (Blinzinger and Kreutzberg 1968), and MHC-I
molecules are important for the balanced excitatory/
inhibitory input synaptic withdrawal that normally occurs
during development of the nervous system and in the
synaptic removal process in axotomized MNs (Schutz
2005; Thams et al. 2008). We observed early activated mi-
croglia surrounding MNs concurrent with a loss of
MHC-I expression within MNs. As the regenerative
capacity is hampered in animals lacking MHC class I sig-
naling (Thams et al. 2008), its early downregulation in
the SOD1G93A transgenic mice may influence both the
unbalanced synaptic stripping and the difficulty in suc-
cessful regeneration described in the model.
The diminution in cholinergic presynaptic boutons
was also extended to changes in the postsynaptic sites,
revealed by loss of Sig1-R immunoreactivity, an ion-
buffering chaperone present in the subsurface cisternae
of MNs underneath presynaptic C-boutons. Undoubt-
edly, this may influence ion channel conductivity and
calcium buffering leading to changes in the pattern of
MN firing and to altered motor behavior as that
observed in the Sig1-R knockout mice (Mavlyutov et al.
2010). Reinforcing the potential etiopathogenic interest
of the Sig1-R alteration is the recent discovery of Sig1-R
mutations linked to some cases of MN disease (Luty
et al. 2010).
Finally, how can an early and general reduction of
cholinergic activity contribute to the different vulnerabil-
ity observed between fast (more vulnerable) and slow
MN types in ALS? One of the possibilities is that
requirement of ACh production is markedly different
between slow and fast MNs because they diverge in the
total number of action potentials fired per day (Hennig
and Lomo 1985) and in the amount of ACh released per
action potential (quantal content). Thus, reduction of
the presynaptic ChAT content may lead to decreased
evoked ACh release, which would affect particularly the
fast MNs. In contrast to the evoked potential, the rate of
spontaneous ACh release is similar between fast and slow
MNs (Reid et al. 1999). However, fast MNs are more
dependent on endplate ACh receptor activation that acts
as a retrograde signaling system for regulating their elec-
trical properties, maintaining connectivity, and promot-
ing regeneration (Reid et al. 1999). In this regard, a
decrease in spontaneous ACh release would consistently
weaken the strength of selective neuromuscular junction
and hinder regeneration as observed in ALS (Murray
et al. 2010).
Conclusion
In conclusion, cholinergic dysfunction in the local cir-
cuitry of the spinal cord may be one of the earliest events
in ALS pathogenesis. Thus, special interest in electrophys-
iological studies to perform repetitive nerve stimulation
or analysis of recurrent inhibition to ascertain early ALS
diagnosis in patients should be taken into consideration.
Besides, the results presented herein suggest that ChAT
production and function may be potential targets for
therapy in ALS.
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